Vicore Pharma (NASDAQ:VCRE) Upgraded at Wall Street Zen

Vicore Pharma (NASDAQ:VCRE) was upgraded by analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Other equities analysts have also issued reports about the stock. Jefferies Financial Group started coverage on shares of Vicore Pharma in a research note on Friday, October 9th. They issued a “buy” rating and a $25.00 target price for the company. Weiss Ratings assumed coverage on shares of Vicore Pharma in a research note on Thursday, October 8th. They set a “sell (e-)” rating for the company. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.00.

Vicore Pharma Price Performance

VCRE stock opened at $9.38 on Friday. Vicore Pharma has a twelve month low of $7.88 and a twelve month high of $17.80.

Vicore Pharma (NASDAQ:VCRE) last posted its quarterly earnings results on Friday, August 21st. The company reported ($0.05) earnings per share for the quarter. The business had revenue of $0.23 million for the quarter.

Vicore Pharma Company Profile

Vicore Pharma is a Swedish biopharmaceutical company focused on developing medicines for severe respiratory and pulmonary diseases. The company’s research is centered on treatments intended to address the underlying disease processes associated with conditions such as idiopathic pulmonary fibrosis and other forms of progressive lung fibrosis.

Vicore’s lead investigational program is buloxibutid, formerly known as C21, an orally administered small-molecule agonist of the angiotensin II type 2 receptor.